Report cover image

OncoCyte Corp (OCX) - Product Pipeline Analysis, 2022 Update

Publisher GlobalData
Published Feb 07, 2023
Length 78 Pages
SKU # GBDT17776357

Description

Summary

OncoCyte Corp (OncoCyte) is a molecular diagnostic company that develops solutions for the detection and treatment of cancer. The company offers DetermaRx, a predictive molecular test to identify patients with early-stage non-squamous non-small cell lung cancer. It also develops DetermaIO, a gene expression test to identify immunotherapy drug responders; and DetermaCNI, a test used to measure and monitor cancer treatment. Oncocyte provides biopharma services such as target discovery; assay design, development and validation; and clinical trial and testing services. The company operates in Germany and the US. OncoCyte is headquartered in Irvine, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:
  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company OncoCyte Corp
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

78 Pages
OncoCyte Corp Company Overview
OncoCyte Corp Company Snapshot
OncoCyte Corp Pipeline Products and Ongoing Clinical Trials Overview
OncoCyte Corp – Pipeline Analysis Overview
OncoCyte Corp - Key Facts
OncoCyte Corp - Major Products and Services
OncoCyte Corp Pipeline Products by Development Stage
OncoCyte Corp Ongoing Clinical Trials by Trial Status
OncoCyte Corp Pipeline Products Overview
ALK Resistance Monitoring Assay
ALK Resistance Monitoring Assay Product Overview
Breast Confirmatory BI RADS 3-4 Assay
Breast Confirmatory BI RADS 3-4 Assay Product Overview
Companion Diagnostic Test - Alzheimer’s Disease
Companion Diagnostic Test - Alzheimer’s Disease Product Overview
Companion Diagnostic Test - Amyotrophic Lateral Sclerosis
Companion Diagnostic Test - Amyotrophic Lateral Sclerosis Product Overview
Companion Diagnostic Test - Breast Cancer
Companion Diagnostic Test - Breast Cancer Product Overview
Companion Diagnostic Test - Chronic Fatigue Syndrome
Companion Diagnostic Test - Chronic Fatigue Syndrome Product Overview
Companion Diagnostic Test - Colorectal Cancer
Companion Diagnostic Test - Colorectal Cancer Product Overview
Companion Diagnostic Test - Multiple Sclerosis
Companion Diagnostic Test - Multiple Sclerosis Product Overview
Companion Diagnostic Test - Parkinson’s Disease
Companion Diagnostic Test - Parkinson’s Disease Product Overview
Companion Diagnostic Test - Prostate Cancer
Companion Diagnostic Test - Prostate Cancer Product Overview
Companion Diagnostic Test - Rheumatoid Arthritis
Companion Diagnostic Test - Rheumatoid Arthritis Product Overview
Dense Breast Tissue Confirmatory Test - Breast Cancer
Dense Breast Tissue Confirmatory Test - Breast Cancer Product Overview
DetermaCNI
DetermaCNI Product Overview
DetermaDx
DetermaDx Product Overview
DetermaIO
DetermaIO Product Overview
DetermaIO Clinical Trial
DetermaMX
DetermaMX Product Overview
DetermaTx
DetermaTx Product Overview
Diagnostic Assay - Amyloidosis
Diagnostic Assay - Amyloidosis Product Overview
Diagnostic Assay - Autism Spectrum Disorder
Diagnostic Assay - Autism Spectrum Disorder Product Overview
Diagnostic Assay - HPV
Diagnostic Assay - HPV Product Overview
Diagnostic Assay - Type I Diabetes
Diagnostic Assay - Type I Diabetes Product Overview
Diagnostic Test - Brain Cancer
Diagnostic Test - Brain Cancer Product Overview
Diagnostic Test - Gulf War Illnesses
Diagnostic Test - Gulf War Illnesses Product Overview
Diagnostic Test - Huntington's Disease
Diagnostic Test - Huntington's Disease Product Overview
Diagnostic Test - Lung Cancer
Diagnostic Test - Lung Cancer Product Overview
Diagnostic Test - Ovarian Cancer
Diagnostic Test - Ovarian Cancer Product Overview
Diagnostic Test - Systemic Lupus Erythematous
Diagnostic Test - Systemic Lupus Erythematous Product Overview
Insight ALK ECD Assay
Insight ALK ECD Assay Product Overview
Insight DEPDC1 Screen Assay
Insight DEPDC1 Screen Assay Product Overview
Insight ROS1 Fusion Screen Assay
Insight ROS1 Fusion Screen Assay Product Overview
KIR/KIR-Ligand LDT Assay
KIR/KIR-Ligand LDT Assay Product Overview
Lung Screening Assay
Lung Screening Assay Product Overview
Next-Generation DetermaVu
Next-Generation DetermaVu Product Overview
NGS Lung Panel Test
NGS Lung Panel Test Product Overview
PanC-Dx - Bladder Cancer
PanC-Dx - Bladder Cancer Product Overview
PanC-Dx - Breast Cancer
PanC-Dx - Breast Cancer Product Overview
PanC-Dx - Breast Cancer Clinical Trial
PanC-Dx - Colon Cancer
PanC-Dx - Colon Cancer Product Overview
PanC-Dx - Lung Cancer
PanC-Dx - Lung Cancer Product Overview
PanC-Dx - Prostate Cancer
PanC-Dx - Prostate Cancer Product Overview
Therapeutic Monitoring Test - Pancreatic Cancer
Therapeutic Monitoring Test - Pancreatic Cancer Product Overview
Therasure Transplant Monitor Test - LDT
Therasure Transplant Monitor Test - LDT Product Overview
Tumor Type 4 Assay
Tumor Type 4 Assay Product Overview
OncoCyte Corp - Key Competitors
OncoCyte Corp - Key Employees
OncoCyte Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
OncoCyte Corp, Recent Developments
Nov 30, 2022: Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
Nov 30, 2022: Oncocyte Announces Executive Leadership Changes
Nov 10, 2022: Oncocyte Reports Third Quarter 2022 Financial Results
Aug 31, 2022: Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
Mar 28, 2022: Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022
Mar 10, 2022: Oncocyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Nov 09, 2021: Oncocyte Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Oct 27, 2021: Oncocyte strengthens transplant intellectual property portfolio with US patent covering digital PCR technology for early detection of organ transplant rejection
Oct 26, 2021: Oncocyte to Report Third Quarter 2021 Financial Results on Tuesday, November 9th
Oct 07, 2021: Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: OncoCyte Corp Pipeline Products and Ongoing Clinical Trials Overview
Table 2: OncoCyte Corp Pipeline Products by Equipment Type
Table 3: OncoCyte Corp Pipeline Products by Indication
Table 4: OncoCyte Corp, Key Facts
Table 5: OncoCyte Corp, Major Products and Services
Table 6: OncoCyte Corp Number of Pipeline Products by Development Stage
Table 7: OncoCyte Corp Pipeline Products Summary by Development Stage
Table 8: OncoCyte Corp Ongoing Clinical Trials by Trial Status
Table 9: OncoCyte Corp Ongoing Clinical Trials Summary
Table 10: ALK Resistance Monitoring Assay - Product Status
Table 11: ALK Resistance Monitoring Assay - Product Description
Table 12: Breast Confirmatory BI RADS 3-4 Assay - Product Status
Table 13: Breast Confirmatory BI RADS 3-4 Assay - Product Description
Table 14: Companion Diagnostic Test - Alzheimer’s Disease - Product Status
Table 15: Companion Diagnostic Test - Alzheimer’s Disease - Product Description
Table 16: Companion Diagnostic Test - Amyotrophic Lateral Sclerosis - Product Status
Table 17: Companion Diagnostic Test - Amyotrophic Lateral Sclerosis - Product Description
Table 18: Companion Diagnostic Test - Breast Cancer - Product Status
Table 19: Companion Diagnostic Test - Breast Cancer - Product Description
Table 20: Companion Diagnostic Test - Chronic Fatigue Syndrome - Product Status
Table 21: Companion Diagnostic Test - Chronic Fatigue Syndrome - Product Description
Table 22: Companion Diagnostic Test - Colorectal Cancer - Product Status
Table 23: Companion Diagnostic Test - Colorectal Cancer - Product Description
Table 24: Companion Diagnostic Test - Multiple Sclerosis - Product Status
Table 25: Companion Diagnostic Test - Multiple Sclerosis - Product Description
Table 26: Companion Diagnostic Test - Parkinson’s Disease - Product Status
Table 27: Companion Diagnostic Test - Parkinson’s Disease - Product Description
Table 28: Companion Diagnostic Test - Prostate Cancer - Product Status
Table 29: Companion Diagnostic Test - Prostate Cancer - Product Description
Table 30: Companion Diagnostic Test - Rheumatoid Arthritis - Product Status
Table 31: Companion Diagnostic Test - Rheumatoid Arthritis - Product Description
Table 32: Dense Breast Tissue Confirmatory Test - Breast Cancer - Product Status
Table 33: Dense Breast Tissue Confirmatory Test - Breast Cancer - Product Description
Table 34: DetermaCNI - Product Status
Table 35: DetermaCNI - Product Description
Table 36: DetermaDx - Product Status
Table 37: DetermaDx - Product Description
Table 38: DetermaIO - Product Status
Table 39: DetermaIO - Product Description
Table 40: DetermaIO - A Phase II, Multicenter, Single-arm Study of Atezolizumab in Patients with Locally Advanced or Metastatic Urothelial Bladder Cancer
Table 41: DetermaIO - A Randomized, Phase Iii Trial to Evaluate the Efficacy and Safety of Pembrolizumab (Mk-3475) as Adjuvant Therapy for Triple Receptor-negative Breast Cancer with ≫/= 1 Cm Residual Invasive Cancer or Positive Lymph Nodes (Ypn1mi, Ypn1-3) after Neoadjuvant Chemotherapy
Table 42: DetermaIO - Neo-adjuvant Study with the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment with Nab-paclitaxel and Carboplatin
Table 43: DetermaIO - Randomized Phase II Study of FOLFOXIRI Plus Bevacizumab Plus Atezolizumab Versus FOLFOXIRI Plus Bevacizumab as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
Table 44: DetermaMX - Product Status
Table 45: DetermaMX - Product Description
Table 46: DetermaTx - Product Status
Table 47: DetermaTx - Product Description
Table 48: Diagnostic Assay - Amyloidosis - Product Status
Table 49: Diagnostic Assay - Amyloidosis - Product Description
Table 50: Diagnostic Assay - Autism Spectrum Disorder - Product Status
Table 51: Diagnostic Assay - Autism Spectrum Disorder - Product Description
Table 52: Diagnostic Assay - HPV - Product Status
Table 53: Diagnostic Assay - HPV - Product Description
Table 54: Diagnostic Assay - Type I Diabetes - Product Status
Table 55: Diagnostic Assay - Type I Diabetes - Product Description
Table 56: Diagnostic Test - Brain Cancer - Product Status
Table 57: Diagnostic Test - Brain Cancer - Product Description
Table 58: Diagnostic Test - Gulf War Illnesses - Product Status
Table 59: Diagnostic Test - Gulf War Illnesses - Product Description
Table 60: Diagnostic Test - Huntington's Disease - Product Status
Table 61: Diagnostic Test - Huntington's Disease - Product Description
Table 62: Diagnostic Test - Lung Cancer - Product Status
Table 63: Diagnostic Test - Lung Cancer - Product Description
Table 64: Diagnostic Test - Ovarian Cancer - Product Status
Table 65: Diagnostic Test - Ovarian Cancer - Product Description
Table 66: Diagnostic Test - Systemic Lupus Erythematous - Product Status
Table 67: Diagnostic Test - Systemic Lupus Erythematous - Product Description
Table 68: Insight ALK ECD Assay - Product Status
Table 69: Insight ALK ECD Assay - Product Description
Table 70: Insight DEPDC1 Screen Assay - Product Status
Table 71: Insight DEPDC1 Screen Assay - Product Description
Table 72: Insight ROS1 Fusion Screen Assay - Product Status
Table 73: Insight ROS1 Fusion Screen Assay - Product Description
Table 74: KIR/KIR-Ligand LDT Assay - Product Status
Table 75: KIR/KIR-Ligand LDT Assay - Product Description
Table 76: Lung Screening Assay - Product Status
Table 77: Lung Screening Assay - Product Description
Table 78: Next-Generation DetermaVu - Product Status
Table 79: Next-Generation DetermaVu - Product Description
Table 80: NGS Lung Panel Test - Product Status
Table 81: NGS Lung Panel Test - Product Description
Table 82: PanC-Dx - Bladder Cancer - Product Status
Table 83: PanC-Dx - Bladder Cancer - Product Description
Table 84: PanC-Dx - Breast Cancer - Product Status
Table 85: PanC-Dx - Breast Cancer - Product Description
Table 86: PanC-Dx - Breast Cancer - Clinical Study of PanC-Dx for Breast Cancer and Other Types of Human Cancers
Table 87: PanC-Dx - Colon Cancer - Product Status
Table 88: PanC-Dx - Colon Cancer - Product Description
Table 89: PanC-Dx - Lung Cancer - Product Status
Table 90: PanC-Dx - Lung Cancer - Product Description
Table 91: PanC-Dx - Prostate Cancer - Product Status
Table 92: PanC-Dx - Prostate Cancer - Product Description
Table 93: Therapeutic Monitoring Test - Pancreatic Cancer - Product Status
Table 94: Therapeutic Monitoring Test - Pancreatic Cancer - Product Description
Table 95: Therasure Transplant Monitor Test - LDT - Product Status
Table 96: Therasure Transplant Monitor Test - LDT - Product Description
Table 97: Tumor Type 4 Assay - Product Status
Table 98: Tumor Type 4 Assay - Product Description
Table 99: OncoCyte Corp, Key Employees
Table 100: OncoCyte Corp, Other Locations
Table 101: OncoCyte Corp, Subsidiaries
Table 102: Glossary
List of Figures
Figure 1: OncoCyte Corp Pipeline Products by Equipment Type
Figure 2: OncoCyte Corp Pipeline Products by Development Stage
Figure 3: OncoCyte Corp Ongoing Clinical Trials by Trial Status

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us